Engineering Commons^™

Net Energy And Greenhouse Gas Emissions Evaluation Of Biodiesel Derived From Microalgae, Liaw Y. Batan

CO2 Summit: Technology and Opportunity

No abstract provided.

A Vaccine Prototype Using Baculovirus Expression System For The Control Of Avian Influenza Virus, Mauricio Realpe, R. Mora, L. Castellanos, F. Robles, C. González-Hernández

Vaccine Technology III

A clade 1 sequence of H5 haemaglutinin from an Asian Avian H5N1 isolate was used as a the template to chemically synthetize a codon optimized version for expression in insect cells. A single clone was chosen for expression optimization and changes were introduced in order to maximize the amount of protein to be produced and to resemble another sequence demonstrated to be present in an isolate causing disease in Humans.

Preliminary analysis at lab scale have shown promising yields of the haemaglutinin using an activity titration assay and an ELISA-based detection method. Optimization of the cell seeding, MOI, and time …

Vaccine Stabilization – Research, Commercialization, And Impact, Ray Cummings, Debra Kristensen, Dexiang Chen, Michel Zaffran

Vaccine Technology III

Improving the stability of vaccines and removing vaccines from refrigerated storage for all or part of their shelf life have been proposed as strategies to help ensure vaccine effectiveness and to mitigate cold chain storage capacity constraints and escalating costs associated with the introduction of new vaccines into developing countries. Over the last six years, PATH has conducted research on stabilization of measles, Haemophilus influenzae type b (Hib), hepatitis B, enterotoxgenic Escherichia coli, conjugate meningococcal A, and pentavalent (Diphtheria-Tetanus-Pertussis-hepatitis B-Hib) vaccines in collaboration with 22 technical partners and 10 vaccine development groups. Results will be shared and include marked improvement …

Achieving Process Energy Efficiency Via Innovation, Greg Werba

CO2 Summit: Technology and Opportunity

No abstract provided.

Unblocking Biofuels With Microchannel Technology, Jeff Mcdaniel

CO2 Summit: Technology and Opportunity

No abstract provided.

Purification Process Development Of Protein Subunit Based Vaccine Candidates Produced Using Recombinant E. Coli Expression System (Part - Ii), Davinder Chawla, Yan-Ping Yang

Vaccine Technology III

Proteins are key components of prophylactic vaccines against infectious diseases. Protein subunit based vaccine is an attractive alternative to the traditional detoxified bacterial or inactivated viral vaccine approach due to its highly purified and well characterized product nature. Purification of protein antigens to achieve consistent product purity and quality is an integral part of the protein subunit vaccine product development process. Expression levels of the recombinant proteins in bacterial expression system may be extremely high following rapid technology advancement. The challenges and approaches used to develop purification processes for novel protein vaccine candidates expressed at g/L level will be discussed.

Iscomatrix™ Adjuvant Links Innate And Adaptive Immune Responses, Debbie Drane

Vaccine Technology III

The ISCOMATRIX™ adjuvant has antigen delivery and presentation properties as well as immunomodulatory capabilities which combine to provide enhanced and accelerated immune responses. The responses are broad, including a range of sub classes of antibodies as well as both CD4+ and CD8+ T cells. A range of ISCOMATRIX™ vaccines (ISCOMATRIX™ adjuvant combined with antigen) have now been tested in clinical trials and have been shown to be generally safe and well tolerated as well as immunogenic, generating both antibody and T cell responses.

The mechanisms by which ISCOMATRIX™ adjuvant facilitates its immune effects is the scope of significant study and …

Solid Fuels Conversion Using The Iron-Based Chemical Looping Process, Ray Kim

CO2 Summit: Technology and Opportunity

No abstract provided.

Co2 Summit: Complete Conference Program, Frank Zhu

CO2 Summit: Technology and Opportunity

Final Conference Program

Assessment Of Strategies Proposed To Reduce Co2 Emissions, Costas Tsouris

CO2 Summit: Technology and Opportunity

No abstract provided.

Development Of A Multi-Dose Formulation For Prevnar 13™, Lakshmi Khandke, Cindy Yang, Jingrun Fan, Hanyoung Han, Ksenia Krylova Abbas Rashidbaigi, Bruce A. Green, Kathrin U. Jansen

Vaccine Technology III

Streptococcus pneumoniae causes up to a million cases per year of invasive disease in young children and infants, most occurring in developing countries. Pfizer is partnering with WHO and the GAVI alliance to support the developing world on immunization against pneumococcal disease. Prevnar 13™ is currently approved for the prevention of invasive pneumococcal disease in twenty seven countries. If used widely, this pneumococcal conjugate vaccine could prevent hundreds of thousands of additional cases of child mortality each year.

Use of single-dose preservative-free vaccine formulations will raise the overall cost of vaccination programs and may jeopardize the effectiveness of immunization programs …

Low Emissions Coal Technology In Australia, John Carras

CO2 Summit: Technology and Opportunity

No abstract provided.

Purification Process Development Of Protein Subunit Based Vaccine Candidates Produced Using Recombinant E. Coli Expression System (Part - I), Davinder Chawla, Yan-Ping Yang

Vaccine Technology III

Proteins are key components of prophylactic vaccines against infectious diseases. Protein subunit based vaccine is an attractive alternative to the traditional detoxified bacterial or inactivated viral vaccine approach due to its highly purified and well characterized product nature. Purification of protein antigens to achieve consistent product purity and quality is an integral part of the protein subunit vaccine product development process. Expression levels of the recombinant proteins in bacterial expression system may be extremely high following rapid technology advancement. The challenges and approaches used to develop purification processes for novel protein vaccine candidates expressed at g/L level will be discussed.

Advanced Biofuels: Commercializing The Efficient Syngas-To-Ethanol Platform, Wes Bolsen

CO2 Summit: Technology and Opportunity

No abstract provided.

Toward Sustainable Co2 Capture, Jae W. Lee

CO2 Summit: Technology and Opportunity

No abstract provided.

Bio-Energy Greenhouse Gases Life Cycle Assessment Review, Helena Chum

CO2 Summit: Technology and Opportunity

No abstract provided.

Aqueous Amine Absorption: Experimentation And Modeling, Clint P. Aichele

CO2 Summit: Technology and Opportunity

No abstract provided.

Efficient Combustion: The Chemical Engineer's Quest?, Diane Hildebrandt

CO2 Summit: Technology and Opportunity

No abstract provided.

Introduction To The Conference, Frank Zhu

CO2 Summit: Technology and Opportunity

No abstract provided.

Abstracts Of Poster Presentations

CO2 Summit: Technology and Opportunity

Abstracts of Poster Presentations

How To Make Cement And Concretes With Lower Co2 Emissions, Ellis Gartner

CO2 Summit: Technology and Opportunity

No abstract provided.

Minimization Of Embodied Energy In Reinforced Concrete, Emil Simiu

CO2 Summit: Technology and Opportunity

No abstract provided.

Greenhouse Gas Capture And Mitigation Techniques For Different Industries, Trapti Chaubey

CO2 Summit: Technology and Opportunity

No abstract provided.

Final Conference Program, Barry Buckland, John Aunins, Paula Marques Alves, Kathrin Jansen

Vaccine Technology III

List of talks during the conference.

Nipah/Hendra: Understanding The Links Between Human And Veterinary Emerging Diseases, Jules Minke

Vaccine Technology III

Animals constitute an important source of infectious diseases for humans and the majority of recent emerging diseases in humans are zoonotic. Infections occur through direct or indirect transmission from wildlife reservoirs or via the food chain. Nipah and Hendra viruses have recently joined the growing list of viruses that emerged from bats to cause serious disease in humans and livestock. Although the precise mode of virus transmission is not fully understood, human infection appears to be the result of close contact with infected horses and pigs that act as amplifying hosts. Improved control strategies are necessary to reduce the transmission …

After The License Approval: How Analytics Can Keep You In The Market, Robert Sitrin

Vaccine Technology III

Getting a BLA approved for a new vaccine can be a daunting task, but keeping the market supplied after licensure of a successful vaccine can be an even bigger challenge. Analytics can play an important role in keeping product supplied to the marketplace, especially during the critical launch phase The talk will describe the application of analytical comparability to GARDASIL®, Merck’s novel new vaccine to prevent cervical cancer, in order to bridge product produced by a launch facility to that produced by a scale-up facility without the need for a clinical trial. This effort assured a smooth transition of supply …

Metabolic Engineering Of A Strain Of Saccharomyces Cerevisiae Capable Of Utilizing Xylose For Growth And Ethanol Production, Ashley Fulton

CO2 Summit: Technology and Opportunity

No abstract provided.

Establishing A Platform For Spray Drying Inhalable Vaccines In South Africa, Willem Germishuizen, L Venter, A Khosa, F Mudau, P.B. Fourie, B Pulliam, M Kabadi, A Schiermeier, D.A . Edwards

Vaccine Technology III

Mycobacterium bovis BCG is the current vaccine for tuberculosis (TB). However, BCG as it is currently administered shows highly variable efficacy in protecting adults against TB. The natural route of infection of TB is via inhalation of bacilli-containing aerosols and it is postulated that immunization by the natural route of infection may lead to a greater immunity given the fact that the lungs are the primary target of infection. By eliciting both local and systemic immune responses, it is anticipated that an inhaled form of BCG will offer greater protection against pulmonary TB.

Current commercial BCG vaccine preparations are filled …

Innovative Therapeutic Cancer Vaccines In Cuba: An Update, Luis Enrique Fernández

Vaccine Technology III

Worldwide cancer affects more than 10 million new people each year while other 22 million are living with this devastating disease.

Cancer vaccines are the newest weapon in the battle against this disease, specifically increasing body's natural abilities to halt tumour progression. Currently, 141 distinct projects are at different stages of clinical development.

The Cuban Biotech System of Institutions has been actively involved in this field for almost 20 years, resulting that 8 innovative therapeutic cancer vaccine projects are currently under clinical investigation.

The main focus of these projects is to impact the principal cancer localizations afecting Cuban population, like …

Application Of Animal-Free Recombinant Bioactive Protein Supplements To Improve The Performance Of Cell-Based Viral Vaccine Production, Kenneth Bertram, Marina Ross, Domenica Cavallaro, Larissa Chirkova, Geoffrey Francis

Vaccine Technology III

Animal cell culture for the production of viral vaccines has been performed for more than 50 years, and currently this technology is expanding rapidly to meet present and future demands of the health sector. The development and regulatory approval of continuous cell lines for manufacturing viral vaccines has brought numerous benefits to production processes. However, greater advances in the last decade have been achieved in mammalian cell production of biological therapeutics, including monoclonal antibodies, hormones, growth factors, cytokines and clotting factors. We and others have contributed to these upstream advances by improving cell culture media with the development of animal-free …